An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

NCT02654132 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Elotuzumab
DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]
[object Object]